64 related articles for article (PubMed ID: 13679162)
1. Docking experiments showing similar recognition patterns of paclitaxel when interacting with different macromolecular targets.
Alcaro S; Battaglia D; Ortuso F
Farmaco; 2003 Sep; 58(9):691-8. PubMed ID: 13679162
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of paclitaxel-conjugated β-cyclodextrin polyrotaxane and its antitumor activity.
Yu S; Zhang Y; Wang X; Zhen X; Zhang Z; Wu W; Jiang X
Angew Chem Int Ed Engl; 2013 Jul; 52(28):7272-7. PubMed ID: 23740531
[No Abstract] [Full Text] [Related]
3. Modeling the interaction of paclitaxel with beta-tubulin.
Ivery MT; Le T
Oncol Res; 2003; 14(1):1-19. PubMed ID: 14552587
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins.
Hamada H; Ishihara K; Masuoka N; Mikuni K; Nakajima N
J Biosci Bioeng; 2006 Oct; 102(4):369-71. PubMed ID: 17116587
[TBL] [Abstract][Full Text] [Related]
5. Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel.
Kim H; Choi J; Kim HW; Jung S
Carbohydr Res; 2002 Mar; 337(6):549-55. PubMed ID: 11890892
[TBL] [Abstract][Full Text] [Related]
6. A molecular docking study of anticancer drug paclitaxel and its analogues.
Sinha R; Vidyarthi AS; Shankaracharya
Indian J Biochem Biophys; 2011 Apr; 48(2):101-5. PubMed ID: 21682141
[TBL] [Abstract][Full Text] [Related]
7. Construction of supramolecular polymers with alternating alpha-, beta-cyclodextrin units using conformational change induced by competitive guests.
Miyauchi M; Harada A
J Am Chem Soc; 2004 Sep; 126(37):11418-9. PubMed ID: 15366870
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes.
Alcaro S; Ventura CA; Paolino D; Battaglia D; Ortuso F; Cattel L; Puglisi G; Fresta M
Bioorg Med Chem Lett; 2002 Jun; 12(12):1637-41. PubMed ID: 12039580
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, modeling, and anti-tubulin activity of a D-seco paclitaxel analogue.
Barboni L; Giarlo G; Ricciutelli M; Ballini R; Georg GI; VanderVelde DG; Himes RH; Wang M; Lakdawala A; Snyder JP
Org Lett; 2004 Feb; 6(4):461-4. PubMed ID: 14961598
[TBL] [Abstract][Full Text] [Related]
10. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.
Agüeros M; Zabaleta V; Espuelas S; Campanero MA; Irache JM
J Control Release; 2010 Jul; 145(1):2-8. PubMed ID: 20347897
[TBL] [Abstract][Full Text] [Related]
11. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
Magnani M; Ortuso F; Soro S; Alcaro S; Tramontano A; Botta M
FEBS J; 2006 Jul; 273(14):3301-10. PubMed ID: 16803461
[TBL] [Abstract][Full Text] [Related]
12. Ab initio conformational study of the phenylisoserine side chain of paclitaxel.
Milanesio M; Ugliengo P; Viterbo D; Appendino G
J Med Chem; 1999 Jan; 42(2):291-9. PubMed ID: 9925734
[TBL] [Abstract][Full Text] [Related]
13. The tubulin-bound conformation of paclitaxel: T-taxol vs "PTX-NY".
Yang Y; Alcaraz AA; Snyder JP
J Nat Prod; 2009 Mar; 72(3):422-9. PubMed ID: 19267457
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting solubilization of a poorly soluble novel tubulin-binding agent.
Shah AK; Wyandt CM
Pharm Dev Technol; 2013; 18(6):1319-28. PubMed ID: 22632122
[TBL] [Abstract][Full Text] [Related]
15. [An oligopeptide improves solubility of paclitaxel by non-covalent interaction].
Liu W; Guo T; Ge JW; Li HY; Xu XJ; Sun LX; Zhang JW
Yao Xue Xue Bao; 2012 Jul; 47(7):947-52. PubMed ID: 22993863
[TBL] [Abstract][Full Text] [Related]
16. Probing the environment of tubulin-bound paclitaxel using fluorescent paclitaxel analogues.
Sengupta S; Boge TC; Liu Y; Hepperle M; Georg GI; Himes RH
Biochemistry; 1997 Apr; 36(17):5179-84. PubMed ID: 9136879
[TBL] [Abstract][Full Text] [Related]
17. The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin.
Entwistle RA; Winefield RD; Foland TB; Lushington GH; Himes RH
FEBS Lett; 2008 Jul; 582(16):2467-70. PubMed ID: 18570892
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.
Ferlini C; Cicchillitti L; Raspaglio G; Bartollino S; Cimitan S; Bertucci C; Mozzetti S; Gallo D; Persico M; Fattorusso C; Campiani G; Scambia G
Cancer Res; 2009 Sep; 69(17):6906-14. PubMed ID: 19671798
[TBL] [Abstract][Full Text] [Related]
19. Comparative binding energy (COMBINE) analysis supports a proposal for the binding mode of epothilones to β-tubulin.
Coderch C; Klett J; Morreale A; Fernando Díaz J; Gago F
ChemMedChem; 2012 May; 7(5):836-43. PubMed ID: 22431398
[TBL] [Abstract][Full Text] [Related]
20. In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC.
Bouquet W; Ceelen W; Adriaens E; Almeida A; Quinten T; De Vos F; Pattyn P; Peeters M; Remon JP; Vervaet C
Ann Surg Oncol; 2010 Sep; 17(9):2510-7. PubMed ID: 20339948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
